{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:08:52Z","timestamp":1790179732039,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["AWD-000533137"],"award-info":[{"award-number":["AWD-000533137"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health","award":["P30CA013148"],"award-info":[{"award-number":["P30CA013148"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD38 is an excellent biomarker and therapeutic target for multiple myeloma due to its high expression on cancerous cells in comparison to healthy cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We aimed to adapt Isatuximab as a PET imaging agent to detect CD38 positive multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      studies confirmed the specificity of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-Isatuximab in CD38\u2009+\u2009OPM-2 and MM.1S cells. Upregulation of CD38 was performed using pomalidomide and ricolinostat. Athymic nude mice were implanted with OPM-2 tumors and PET\/CT images were collected 24\u00a0h, 3d, and 7d post-injection. Dosimetry data was collected from male and female mice and calculated using OLINDA. Three productions of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-Isatuximab were produced using GMP techniques and validated for use in the clinic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Upregulation of CD38 was observed\n                      <jats:italic>in vitro<\/jats:italic>\n                      in CD38\u2009+\u2009cells when treated with either pomalidomide or ricolinostat.\n                      <jats:italic>In vivo<\/jats:italic>\n                      evaluation of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-Isatuximab showed high selectivity in OPM-2 xenografts. Blocking with an excess of unlabeled Isatuximab reduced the tumor accumulation of [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-Isatuximab by 45.5\u201348.5% confirming the\n                      <jats:italic>in vivo<\/jats:italic>\n                      specificity of this radiotracer. Dosimetry calculations were performed and showed an estimated effective dose of 0.359\u00a0mSv\/MBq in females and 0.327\u00a0mSv\/MBq in males. Three clinical grade [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-Isatuximab doses using good manufacturing practices were synthesized which passed all quality control requirements and were stable up to 6\u00a0h, thus validating this compound for use in future clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>89<\/jats:sup>\n                      Zr]Zr-DFO-Isatuximab showed high specificity to CD38 positive cells, had estimated effective doses comparable to other clinically relevant\n                      <jats:sup>89<\/jats:sup>\n                      Zr-labeled antibodies, and can be prepared using GMP practices for clinical use.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11307-025-02062-9","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:18:59Z","timestamp":1765293539000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PET Imaging of CD38 and IND enabling studies of [89Zr]Zr-DFO-Isatuximab"],"prefix":"10.1007","volume":"28","author":[{"given":"Brian D.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey A.","family":"Houson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solana","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Gultekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"McConathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-0191","authenticated-orcid":false,"given":"Suzanne E.","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"3","key":"2062_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2062_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D (2016) Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 43(6):676\u2013681. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.004","journal-title":"Semin Oncol"},{"issue":"3","key":"2062_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/ejh.14225","volume":"113","author":"O Decaux","year":"2024","unstructured":"Decaux O, Fontan J, Perrot A et al (2024) Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma in real-world: the retrospective IMAGE study. Eur J Haematol 113(3):290\u2013297. https:\/\/doi.org\/10.1111\/ejh.14225","journal-title":"Eur J Haematol"},{"issue":"1","key":"2062_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/ejh.12478","volume":"95","author":"SS Chawla","year":"2015","unstructured":"Chawla SS, Kumar SK, Dispenzieri A et al (2015) Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol 95(1):57\u201364. https:\/\/doi.org\/10.1111\/ejh.12478","journal-title":"Eur J Haematol"},{"issue":"1","key":"2062_CR5","first-page":"81","volume":"20","author":"RL da Silva","year":"2011","unstructured":"da Silva RL, Monteiro A, Veiga J (2011) Non-secretory multiple myeloma relapsing as extramedullary liver plasmacytomas. J Gastrointest Liver Dis 20(1):81\u20133","journal-title":"J Gastrointest Liver Dis"},{"issue":"5","key":"2062_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","volume":"12","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Korde N, Lesokhin AM et al (2015) Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 12(5):286\u2013295. https:\/\/doi.org\/10.1038\/nrclinonc.2014.239","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"2062_CR7","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/cncr.32065","volume":"125","author":"AK Nooka","year":"2019","unstructured":"Nooka AK, Kaufman JL, Hofmeister CC et al (2019) Daratumumab in multiple myeloma. Cancer 125(14):2364\u20132382. https:\/\/doi.org\/10.1002\/cncr.32065","journal-title":"Cancer"},{"issue":"17","key":"2062_CR8","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","volume":"20","author":"J Deckert","year":"2014","unstructured":"Deckert J, Wetzel MC, Bartle LM et al (2014) SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 20(17):4574\u20134583. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0695","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2062_CR9","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","volume":"25","author":"L Moreno","year":"2019","unstructured":"Moreno L, Perez C, Zabaleta A et al (2019) The mechanism of action of the anti-CD38 monoclonal antibody Isatuximab in multiple myeloma. Clin Cancer Res 25(10):3176\u20133187. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1597","journal-title":"Clin Cancer Res"},{"issue":"10214","key":"2062_CR10","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson P, Rajkumar S (2019) Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394(10214):2096\u20132107","journal-title":"Lancet"},{"issue":"13 Supplement","key":"2062_CR11","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1158\/1538-7445.AM2019-2966","volume":"79","author":"Z Song","year":"2019","unstructured":"Song Z, Yang G (2019) Wang A Abstract 2966: Isatuximab-induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors. Cancer Res 79(13 Supplement):2966\u20132966","journal-title":"Cancer Res"},{"issue":"1","key":"2062_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/ph5010079","volume":"5","author":"AJ Chang","year":"2012","unstructured":"Chang AJ, DeSilva R, Jain S et al (2012) 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors. Pharmaceuticals 5(1):79\u201393. https:\/\/doi.org\/10.3390\/ph5010079","journal-title":"Pharmaceuticals"},{"issue":"11","key":"2062_CR13","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1021\/mp500323d","volume":"11","author":"BV Marquez","year":"2014","unstructured":"Marquez BV, Ikotun OF, Zheleznyak A (2014) Evaluation of 89Zr-pertuzumab in breast cancer xenografts. Mol Pharm 11(11):3988\u20133995. https:\/\/doi.org\/10.1021\/mp500323d","journal-title":"Mol Pharm"},{"issue":"6","key":"2062_CR14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","volume":"18","author":"R Laforest","year":"2016","unstructured":"Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA (2016) [89Zr] trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer. Molecul Imag Biol 18(6):952\u20139","journal-title":"Molecul Imag Biol"},{"issue":"9","key":"2062_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jlcr.3605","volume":"61","author":"BN McKnight","year":"2018","unstructured":"McKnight BN, Viola-Villegas NT (2018) 89Zr\u2010ImmunoPET companion diagnostics and their impact in clinical drug development. J Labelled Comp Radiopharm 61(9):727\u2013738. https:\/\/doi.org\/10.1002\/jlcr.3605","journal-title":"J Labelled Comp Radiopharm"},{"issue":"25","key":"2062_CR16","doi-asserted-by":"publisher","first-page":"22486","DOI":"10.1021\/acsomega.3c00624","volume":"8","author":"N Herrero Alvarez","year":"2023","unstructured":"Herrero Alvarez N, Michel AL, Viray TD et al (2023) 89Zr-DFO-Isatuximab for CD38-targeted immunoPET imaging of multiple myeloma and lymphomas. ACS Omega 8(25):22486\u201322495. https:\/\/doi.org\/10.1021\/acsomega.3c00624","journal-title":"ACS Omega"},{"issue":"3","key":"2062_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1148\/radiol.2020192621","volume":"295","author":"GA Ulaner","year":"2020","unstructured":"Ulaner GA, Sobol NB, O\u2019Donoghue JA et al (2020) CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging. Radiology 295(3):606\u2013615. https:\/\/doi.org\/10.1148\/radiol.2020192621","journal-title":"Radiology"},{"issue":"8","key":"2062_CR18","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","volume":"45","author":"L Kang","year":"2018","unstructured":"Kang L, Jiang D, England CG et al (2018) Immunopet imaging of CD38 in murine lymphoma models using 89Zr-labeled Daratumumab. Eur J Nucl Med Mol Imaging 45(8):1372\u20131381. https:\/\/doi.org\/10.1007\/s00259-018-3941-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2062_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/jnumed.117.196063","volume":"59","author":"A Ghai","year":"2018","unstructured":"Ghai A, Maji D, Cho N et al (2018) Preclinical development of CD38-targeted [89 Zr]Zr-DFO-daratumumab for imaging multiple myeloma. J Nucl Med 59(2):216\u2013222. https:\/\/doi.org\/10.2967\/jnumed.117.196063","journal-title":"J Nucl Med"},{"issue":"12","key":"2062_CR20","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1038\/s41375-021-01262-w","volume":"35","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Karanes C, Bensinger WI et al (2021) Final results of a phase 1b study of Isatuximab short-duration fixed-volume infusion combination therapy for relapsed\/refractory multiple myeloma. Leukemia 35(12):3526\u20133533. https:\/\/doi.org\/10.1038\/s41375-021-01262-w","journal-title":"Leukemia"},{"issue":"6","key":"2062_CR21","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjh.13905","volume":"172","author":"E Rychak","year":"2016","unstructured":"Rychak E, Mendy D, Shi T et al (2016) Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol 172(6):889\u2013901. https:\/\/doi.org\/10.1111\/bjh.13905","journal-title":"Br J Haematol"},{"issue":"1","key":"2062_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","volume":"35","author":"E Garc\u00eda-Guerrero","year":"2021","unstructured":"Garc\u00eda-Guerrero E, G\u00f6tz R, Doose S et al (2021) Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of Daratumumab. Leukemia 35(1):201\u2013214. https:\/\/doi.org\/10.1038\/s41375-020-0840-y","journal-title":"Leukemia"},{"key":"2062_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1486948","author":"J Ghose","year":"2018","unstructured":"Ghose J, Viola D, Terrazas C (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. https:\/\/doi.org\/10.1080\/2162402X.2018.1486948","journal-title":"Oncoimmunology"},{"key":"2062_CR24","doi-asserted-by":"crossref","unstructured":"Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72(1):77\u201389","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"2062_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00893-z","volume":"12","author":"F Cicone","year":"2022","unstructured":"Cicone F, Viertl D, Deno\u00ebl T et al (2022) Comparison of absorbed dose extrapolation methods for mouse-to-human translation of radiolabelled macromolecules. EJNMMI Res 12:21. https:\/\/doi.org\/10.1186\/s13550-022-00893-z","journal-title":"EJNMMI Res"},{"issue":"3","key":"2062_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G et al (2009) MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med 50(3):477\u2013484. https:\/\/doi.org\/10.2967\/jnumed.108.056036","journal-title":"J Nucl Med"},{"key":"2062_CR27","doi-asserted-by":"publisher","unstructured":"United States Pharmacopeia (2018) General chapter, <85> bacterial endotoxins test. Rockville, MD: USP-NF. https:\/\/doi.org\/10.31003\/USPNF_M98830_02_01","DOI":"10.31003\/USPNF_M98830_02_01"},{"issue":"5","key":"2062_CR28","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","volume":"101","author":"E Drent","year":"2016","unstructured":"Drent E, Groen RWJ, Noort WA et al (2016) Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica 101(5):616\u2013625. https:\/\/doi.org\/10.3324\/haematol.2015.137620","journal-title":"Haematologica"},{"key":"2062_CR29","doi-asserted-by":"publisher","unstructured":"Greenstein S, Krett NL, Kurosawa Y, et al Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 31:4:271\u2013282. https:\/\/doi.org\/10.1016\/S0301-472X(03)00023-7. 2003","DOI":"10.1016\/S0301-472X(03)00023-7"},{"key":"2062_CR30","doi-asserted-by":"publisher","unstructured":"Laban KG, Kalmann R, Leguit RJ, de Keizer B Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease. EJNMMI Res 9:1. https:\/\/doi.org\/10.1186\/s13550-019-0530-9. 2019","DOI":"10.1186\/s13550-019-0530-9"},{"key":"2062_CR31","doi-asserted-by":"publisher","unstructured":"Zakaly HMH, Mostafa MYA, Zhukovsky M Biokinetic modelling of 89Zr-labelled monoclonal antibodies for dosimetry assessment in humans. International Journal of Radiation Research 18:4:825\u2013833. https:\/\/doi.org\/10.18869\/acadpub.ijrr.18.4.825. 2020","DOI":"10.18869\/acadpub.ijrr.18.4.825"},{"issue":"1","key":"2062_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE et al (2017) Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma. Blood 130(1):30\u201334. https:\/\/doi.org\/10.1182\/blood-2017-03-774422","journal-title":"Blood"},{"issue":"6","key":"2062_CR33","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A et al (2019) Low hexokinase-2 expression-associated false-negative18F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging 46(6):1345\u20131350. https:\/\/doi.org\/10.1007\/s00259-019-04312-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2062_CR34","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","volume":"184","author":"MA Bredella","year":"2005","unstructured":"Bredella MA, Steinbach L, Caputo G et al (2005) Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 184(4):1199\u20131204","journal-title":"AJR Am J Roentgenol"},{"key":"2062_CR35","unstructured":"Bhat S, Arora M, Long E, et al Factors influencing Quality of FDG PET\/CT scan in Multiple Myeloma. Journal of Nuclear Medicine 58:supplement 1:1117. 2017"},{"issue":"6","key":"2062_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s13244-010-0062-3","volume":"2","author":"NM Long","year":"2011","unstructured":"Long NM, Smith CS (2011) Causes and imaging features of false positives and false negatives on 18F-PET\/CT in oncologic imaging. Insights Imaging 2(6):679\u2013698. https:\/\/doi.org\/10.1007\/s13244-010-0062-3","journal-title":"Insights Imaging"},{"key":"2062_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2052658","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti A, Ciofini S, Simoncelli M (2022) Anti CD38 monoclonal antibodies for multiple myeloma treatment. Hum Vaccin Immunother. https:\/\/doi.org\/10.1080\/21645515.2022.2052658","journal-title":"Hum Vaccin Immunother"},{"issue":"21","key":"2062_CR38","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.v124.21.3474.3474","volume":"124","author":"JL van Bueren","year":"2014","unstructured":"van Bueren JL, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, Voorhorst M, Gresnigt E, Wiegman L, Buijsse AO, Andringa G (2014) Direct in vitro comparison of daratumumab with surrogate analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79. Blood 124(21):3474. https:\/\/doi.org\/10.1182\/blood.v124.21.3474.3474","journal-title":"Blood"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02062-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02062-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02062-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:16:13Z","timestamp":1772817373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02062-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02062-9","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}